• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/1/21 3:15:37 PM ET
    $CLSN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLSN alert in real time by email
    SC 13G 1 formsc13g.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. N/A)*

     

    Celsion Corporation

    (Name of Issuer)

     

    Ordinary Shares, $0.01 Per share per share

    (Title of Class of Securities)

     

    15117N503

    (CUSIP Number)

     

    January 22, 2021

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [  ] Rule 13d-1(b)

     

    [X] Rule 13d-1(c)

     

    [  ] Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 15117N503

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Ayrton Capital LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a) [  ]
    (b) [X]

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware, U.S.A

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    5,555,555*

    6.

    SHARED VOTING POWER

     

    0

    7.

    SOLE DISPOSITIVE POWER

     

    5,555,555*

    8.

    SHARED DISPOSITIVE POWER

     

    0

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,555,555*

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    [  ]

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.95%*

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

    *The ownership information above is as of the end of business day on January 22, 2021, the day on which the filing of this Schedule 13G was triggered.

     

     

     

     

    CUSIP No. 15117N503

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a) [  ]
    (b) [X]

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER

     

    5,555,555*

    6.

    SHARED VOTING POWER

     

    0

    7.

    SOLE DISPOSITIVE POWER

     

    5,555,555*

    8.

    SHARED DISPOSITIVE POWER

     

    0

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,555,555*

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    [  ]

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.95%*

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    CO

    *The ownership information above is as of the end of business day on January 22, 2021, the day on which the filing of this Schedule 13G was triggered.

     

     

     

     

    CUSIP No. 15117N503

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Waqas Khatri

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a) [  ]
    (b) [X]

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Pakistan

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    5,555,555*

    6.

    SHARED VOTING POWER

     

    0

    7.

    SOLE DISPOSITIVE POWER

     

    5,555,555*

    8.

    SHARED DISPOSITIVE POWER

     

    0

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,555,555*

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    [  ]

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.95%*

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

    *The ownership information above is as of the end of business day on January 22, 2021, the day on which the filing of this Schedule 13G was triggered.

     

     

     

     

    Item 1. (a). Name of Issuer:
         
        Celsion Corporation (the “Issuer”)
         
      (b). Address of issuer’s principal executive offices:
         
       

    997 Lenox Drive

    Suite 100

        Lawrenceville, NJ 08648
         
    Item 2. (a). Name of person filing:
         
        Ayrton Capital LLC
       

    Alto Opportunity Master Fund SPC -Segregated Master Portfolio B

    Waqas Khatri

         
        Address or principal business office or, if none, residence:
         
         
      (b). Ayrton Capital, LLC
        55 Post Rd West, 2nd Floor
        Westport, CT 06880
         
        Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B
        Suite #7, Grand Pavilion Commercial Centre
       

    802 West Bay Road

    Grand Cayman

    P.O. Box 10250

    Cayman Islands

       

     

    Waqas Khatri

    55 Post Rd West, 2nd Floor

    Westport, CT 06880

         
      (c). Citizenship:
         
       

    Ayrton Capital LLC – Delaware Limited Liability Company

    Alto Opportunity Master Fund SPC – Segregated Master Portfolio B – Cayman Islands

        Waqas Khatri – Pakistan
         
      (d) Title of class of securities:
         
        Ordinary Shares, $0.01 Per share  
         
        CUSIP No.:
         
      (e). 15117N503
         
         
         
         
         

     

     

     

     

    Item 3.

    If This Statement is filed pursuant to §§.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a

     

    N/A

     

    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a) Amount beneficially owned:

     

    Ayrton Capital LLC – 5,555,555*

    Alto Opportunity Master Fund SPC – Segregated Master Portfolio B – 5,555,555*

    Waqas Khatri – 5,555,555*

     

      (b) Percent of class:

     

    Ayrton Capital LLC – 8.95%*

    Alto Opportunity Master Fund SPC – Segregated Master Portfolio B – 8.95%*

    Waqas Khatri – 8.95 %*

     

      (c) Number of shares as to which Ayrton Capital LLC has:

     

      (i) Sole power to vote or to direct the vote   5,555,555* ,
               
      (ii) Shared power to vote or to direct the vote   0 ,
               
      (iii) Sole power to dispose or to direct the disposition of   5,555,555* ,
               
      (iv) Shared power to dispose or to direct the disposition of   0 .
               
      Number of shares as to which has: Alto Opportunity Master Fund SPC – Segregated Master Portfolio B      
               
      (i) Sole power to vote or to direct the vote   5,555,555* ,
               
      (ii) Shared power to vote or to direct the vote   0 ,
               
      (iii) Sole power to dispose or to direct the disposition of   5,555,555* ,
               
      (iv) Shared power to dispose or to direct the disposition of   0 .
               
      Number of shares as to which Waqas Khatri has:      
               
      (i) Sole power to vote or to direct the vote   5,555,555* ,
               
      (ii) Shared power to vote or to direct the vote   0 ,
               
      (iii) Sole power to dispose or to direct the disposition of   5,555,555* ,
               
      (iv) Shared power to dispose or to direct the disposition of   0 .

     

     

     

     

    *Shares reported herein were held by Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B (the “Fund”), a Cayman Islands exempted company (all of the foregoing, collectively, the “Reporting Persons”). The Fund is a private investment vehicle for which Ayrton Capital LLC (the “Investment Manager”) serves as the investment manager and Waqas Khatri serves as the managing member of the Investment Manager. The shares consist of 5,555,555 ordinary shares as of January 22, 2021. As of January 28, 2021, the Adviser owned 0 ordinary shares.

     

    By virtue of these relationships, the Reporting Persons may be deemed to have sole voting and dispositive power with respect to the shares owned directly by the Fund. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the shares for purposes of Section 13 of the Exchange Act 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of the Reporting Person’s pecuniary interest therein.

     

    The percentage herein are calculated based upon a statement in the Issuer’s 425B5 filed on January 25, 2021 that there were 62,085,705 ordinary shares issued and outstanding as of January 22, 2021.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. [X]

     

    N/A

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

     

    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

     

    N/A

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    If a parent holding company or control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

     

    N/A

     

     

     

     

    Item 8. Identification and Classification of Members of the Group.

     

    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d- 1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group.

     

    N/A

     

    Item 9. Notice of Dissolution of Group.

     

    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

     

    N/A

     

    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 1, 2021 Ayrton Capital LLC
         
      By: /s/ Waqas Khatri
      Name: Waqas Khatri
      Title: Managing Member
         
      Alto Opportunity Master Fund SPC – Segregated Master Portfolio B
         
      By: /s/ Waqas Khatri
      Name: Waqas Khatri
      Title: Managing Member
         
      Ayrton Capital LLC
       
      By Waqas Khatri
         
      By: /s/ Waqas Khatri
      Name: Waqas Khatri
      Title: Managing Member

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

     

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

     

    Get the next $CLSN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLSN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CLSN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Celsion Corporation Announces Company Name Change to Imunon, Inc.

      New name reflects the evolution of the Company's business focus and its commitment to immunotherapies and vaccines LAWRENCEVILLE, N.J., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage drug development company, today announced a company name change to Imunon, Inc., reflecting the evolution of the Company's business focus and its commitment to developing cutting-edge immunotherapies and next-generation vaccines to treat cancer and infectious diseases. The Company's common stock will trade on the Nasdaq Stock Market under the new ticker symbol "IMNN" effective as of the opening of trading on September 21, 2022. The Company has filed an amendmen

      9/19/22 4:30:00 PM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

      110 Patients Enrolled in Study Comparing Novel Gene-Mediated Immunotherapy plus Neoadjuvant Chemotherapy versus Neoadjuvant Chemotherapy Alone LAWRENCEVILLE, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that its Phase I/II OVATION 2 Study with GEN-1 in advanced ovarian cancer has completed enrollment with 110 patients. GEN-1 is the Company's IL-12 gene-mediated immunotherapy. Topline results are expected in the second half of 2023. The OVATION 2 Study combines GEN-1 with standard-of-care neoadjuvant chemotherapy (NACT) in patients newly diagnosed with S

      9/15/22 8:30:00 AM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30 p.m. ET on September 13

      LAWRENCEVILLE, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage drug development company, announces that Dr. Corinne Le Goff, President and Chief Executive Officer, will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference on September 13th at 4:30 p.m. Eastern time. The presentation will available live and on-demand here. As previously announced, the conference will be held September 12-14 with in-person participation at the Lotte New York Palace Hotel. Dr. Le Goff is also available for in-person meetings at the conference. About Celsion Corporation Celsion is a fully integrated, clinical-stage biotechnol

      9/12/22 6:30:00 PM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLSN
    Financials

    Live finance-specific insights

    See more

    $CLSN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Celsion Corporation to Hold Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 15, 2022

      LAWRENCEVILLE, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. ET on Monday, August 15, 2022 to discuss financial results for the second quarter ended June 30, 2022 and provide an update on product development programs with GEN-1, a DNA-based immunotherapy, currently in Phase II development for the localized treatment of advanced ovarian cancer and PLACCINE, a proprietary synthetic, non-viral vaccine delivery technology currently in preclinical studies. Celsion has two platform technologie

      8/8/22 8:30:00 AM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celsion Corporation to Hold First Quarter 2022 Financial Results and Business Update Conference Call on Monday, May 16, 2022

      LAWRENCEVILLE, N.J., May 09, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. ET on Monday, May 16, 2022 to discuss financial results for the first quarter ended March 31, 2022 and provide an update on product development programs with GEN-1, a DNA-based immunotherapy, currently in Phase II development for the localized treatment of advanced ovarian cancer and PLACCINE, a proprietary synthetic, non-viral vaccine delivery technology currently in preclinical studies. Celsion has two platform technologies fo

      5/9/22 8:30:00 AM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celsion Corporation to Hold Year-End 2021 Financial Results and Business Update Conference Call on Thursday, March 31, 2022

      LAWRENCEVILLE, N.J., March 24, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. ET on Thursday, March 31, 2022 to discuss financial results for the year ended December 31, 2021 and provide an update on product development programs with GEN-1, a DNA-based immunotherapy, currently in Phase II development for the localized treatment of advanced ovarian cancer and PLACCINE, a proprietary synthetic, non-viral vaccine delivery technology currently in preclinical studies. Celsion has two platform technologies fo

      3/24/22 9:00:00 AM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Celsion Corporation (Amendment)

      SC 13G/A - Celsion CORP (0000749647) (Subject)

      2/14/22 3:17:01 PM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Celsion Corporation (Amendment)

      SC 13G/A - Celsion CORP (0000749647) (Subject)

      2/11/22 6:10:51 AM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed

      SC 13G - Celsion CORP (0000749647) (Subject)

      2/1/21 3:15:37 PM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLSN
    Leadership Updates

    Live Leadership Updates

    See more
    • Celsion Appoints Dr. Corinne Le Goff as President and Chief Executive Officer

      Michael H. Tardugno appointed Executive Chairman of the Board LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that the Company's Board of Directors has appointed biopharmaceutical leader Corinne Le Goff, Pharm D, MBA, as President and Chief Executive Officer and Director, effective July 18, 2022. Current President and CEO Michael H. Tardugno will continue to serve as Executive Chairman of Celsion's Board of Directors. Dr. Le Goff brings decades of global healthcare leadership experience to the Company across a range of therapeutic areas i

      7/19/22 8:30:00 AM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Science 37® Appoints Christine Pellizzari as Chief Legal Officer

      With this important addition to its executive team, Science 37 will further advance its mission to accelerate clinical trials by enabling universal access to patients and providers Science 37, pioneer of the Decentralized Clinical Trial Operating System™ (DCT OS), today announced that Christine Pellizzari has joined the senior executive team as Chief Legal Officer. In this role, Ms. Pellizzari will use her nearly 30 years of legal expertise to manage the legal and quality functions to help advance Science 37's mission to enable universal access to clinical research for patients and providers, anywhere. This press release features multimedia. View the full release here: https://www.business

      9/1/21 7:55:00 AM ET
      $CLSN
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celsion Appoints Christine A. Pellizzari to its Board of Directors

      Brings extensive biopharmaceutical legal background to the Board Appointment increases the size of Celsion’s Board from seven to eight Directors LAWRENCEVILLE, N.J., June 09, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced the appointment of Christine A. Pellizzari to the Celsion Board of Directors, effective June 8, 2021. Ms. Pellizzari is Chief Legal Officer of Insmed Incorporated (NASDAQ: INSM), a global biopharmaceutical company dedicated to transforming the lives of patients with serious and rare diseases and brings to Celsion more than 20 years of leadership i

      6/9/21 8:00:00 AM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLSN
    SEC Filings

    See more
    • SEC Form S-1/A filed by Celsion Corporation (Amendment)

      S-1/A - Imunon, Inc. (0000749647) (Filer)

      2/9/24 4:09:15 PM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celsion Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Imunon, Inc. (0000749647) (Filer)

      12/29/23 4:30:19 PM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-1 filed by Celsion Corporation

      S-1 - Imunon, Inc. (0000749647) (Filer)

      12/20/23 5:15:25 PM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLSN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Hazard Sebastien was granted 20,000 shares (SEC Form 4)

      4 - Imunon, Inc. (0000749647) (Issuer)

      12/11/23 4:07:24 PM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Hazard Sebastien claimed no ownership of stock in the company (SEC Form 3)

      3 - Imunon, Inc. (0000749647) (Issuer)

      12/11/23 4:05:23 PM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Braun Donald P

      4 - Imunon, Inc. (0000749647) (Issuer)

      3/21/23 4:42:32 PM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care